Peripheral artery disease and omega-3-polyunsaturated fatty acids

Keita Odashiro, Masahiko Fujihara, Eishi Karashima, Tadashi Mori, Akihiro Koike, Takeshi Kaneko, Toru Maruyama, Koichi Akashi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Peripheral artery disease (PAD) in lower extremities is very common and recognized as a worldwide health burden. Conventional risk factors such as smoking, hypertension, dyslipidemia and type 2 diabetes melllitus have a profound impact on the development and progression of PAD. Besides these risk factors, serum polyunsaturated fatty acids (PUFA) profile, measured as eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA), has been drawing increasing attention as a novel risk factor for atherosclerosis. EPA has unique and diverse anti-inflammatory, antiplatelet, and anti-oxidant effects, with a variety of cardiovascular and endothelial protective actions. Serum PUFA profile may serve as a simple and valuable risk prediction tool to screen the asymptomatic patients for atherosclerotic disease, including PAD. This chapter emphasizes the importance of serum PUFA profile in our Japanese patient population with femoropopliteal or infrapopliteal PAD requiring percutaneous endovascular therapy. Despite the evidence about the impact of EPA/AA ratio on PAD, the therapeutic effects of intensive purified EPA supplementation on prevention and regression of PAD are conflicting and warrant future large-scale prospective studies and randomized trials.

Original languageEnglish
Title of host publicationPeripheral Artery Disease (PAD)
Subtitle of host publicationRisk Factors, Diagnosis and Emerging Treatments
PublisherNova Science Publishers, Inc.
Pages85-100
Number of pages16
ISBN (Electronic)9781634849036
ISBN (Print)9781634848800
Publication statusPublished - Jan 1 2016

Fingerprint

Peripheral Arterial Disease
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Eicosapentaenoic Acid
Arachidonic Acid
Serum
Therapeutic Uses
Dyslipidemias
Type 2 Diabetes Mellitus
Lower Extremity
Atherosclerosis
Anti-Inflammatory Agents
Antioxidants
Smoking
Prospective Studies
Hypertension
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Odashiro, K., Fujihara, M., Karashima, E., Mori, T., Koike, A., Kaneko, T., ... Akashi, K. (2016). Peripheral artery disease and omega-3-polyunsaturated fatty acids. In Peripheral Artery Disease (PAD): Risk Factors, Diagnosis and Emerging Treatments (pp. 85-100). Nova Science Publishers, Inc..

Peripheral artery disease and omega-3-polyunsaturated fatty acids. / Odashiro, Keita; Fujihara, Masahiko; Karashima, Eishi; Mori, Tadashi; Koike, Akihiro; Kaneko, Takeshi; Maruyama, Toru; Akashi, Koichi.

Peripheral Artery Disease (PAD): Risk Factors, Diagnosis and Emerging Treatments. Nova Science Publishers, Inc., 2016. p. 85-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Odashiro, K, Fujihara, M, Karashima, E, Mori, T, Koike, A, Kaneko, T, Maruyama, T & Akashi, K 2016, Peripheral artery disease and omega-3-polyunsaturated fatty acids. in Peripheral Artery Disease (PAD): Risk Factors, Diagnosis and Emerging Treatments. Nova Science Publishers, Inc., pp. 85-100.
Odashiro K, Fujihara M, Karashima E, Mori T, Koike A, Kaneko T et al. Peripheral artery disease and omega-3-polyunsaturated fatty acids. In Peripheral Artery Disease (PAD): Risk Factors, Diagnosis and Emerging Treatments. Nova Science Publishers, Inc. 2016. p. 85-100
Odashiro, Keita ; Fujihara, Masahiko ; Karashima, Eishi ; Mori, Tadashi ; Koike, Akihiro ; Kaneko, Takeshi ; Maruyama, Toru ; Akashi, Koichi. / Peripheral artery disease and omega-3-polyunsaturated fatty acids. Peripheral Artery Disease (PAD): Risk Factors, Diagnosis and Emerging Treatments. Nova Science Publishers, Inc., 2016. pp. 85-100
@inbook{cec489a5bb554258b96b6ec5cbb7e090,
title = "Peripheral artery disease and omega-3-polyunsaturated fatty acids",
abstract = "Peripheral artery disease (PAD) in lower extremities is very common and recognized as a worldwide health burden. Conventional risk factors such as smoking, hypertension, dyslipidemia and type 2 diabetes melllitus have a profound impact on the development and progression of PAD. Besides these risk factors, serum polyunsaturated fatty acids (PUFA) profile, measured as eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA), has been drawing increasing attention as a novel risk factor for atherosclerosis. EPA has unique and diverse anti-inflammatory, antiplatelet, and anti-oxidant effects, with a variety of cardiovascular and endothelial protective actions. Serum PUFA profile may serve as a simple and valuable risk prediction tool to screen the asymptomatic patients for atherosclerotic disease, including PAD. This chapter emphasizes the importance of serum PUFA profile in our Japanese patient population with femoropopliteal or infrapopliteal PAD requiring percutaneous endovascular therapy. Despite the evidence about the impact of EPA/AA ratio on PAD, the therapeutic effects of intensive purified EPA supplementation on prevention and regression of PAD are conflicting and warrant future large-scale prospective studies and randomized trials.",
author = "Keita Odashiro and Masahiko Fujihara and Eishi Karashima and Tadashi Mori and Akihiro Koike and Takeshi Kaneko and Toru Maruyama and Koichi Akashi",
year = "2016",
month = "1",
day = "1",
language = "English",
isbn = "9781634848800",
pages = "85--100",
booktitle = "Peripheral Artery Disease (PAD)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Peripheral artery disease and omega-3-polyunsaturated fatty acids

AU - Odashiro, Keita

AU - Fujihara, Masahiko

AU - Karashima, Eishi

AU - Mori, Tadashi

AU - Koike, Akihiro

AU - Kaneko, Takeshi

AU - Maruyama, Toru

AU - Akashi, Koichi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Peripheral artery disease (PAD) in lower extremities is very common and recognized as a worldwide health burden. Conventional risk factors such as smoking, hypertension, dyslipidemia and type 2 diabetes melllitus have a profound impact on the development and progression of PAD. Besides these risk factors, serum polyunsaturated fatty acids (PUFA) profile, measured as eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA), has been drawing increasing attention as a novel risk factor for atherosclerosis. EPA has unique and diverse anti-inflammatory, antiplatelet, and anti-oxidant effects, with a variety of cardiovascular and endothelial protective actions. Serum PUFA profile may serve as a simple and valuable risk prediction tool to screen the asymptomatic patients for atherosclerotic disease, including PAD. This chapter emphasizes the importance of serum PUFA profile in our Japanese patient population with femoropopliteal or infrapopliteal PAD requiring percutaneous endovascular therapy. Despite the evidence about the impact of EPA/AA ratio on PAD, the therapeutic effects of intensive purified EPA supplementation on prevention and regression of PAD are conflicting and warrant future large-scale prospective studies and randomized trials.

AB - Peripheral artery disease (PAD) in lower extremities is very common and recognized as a worldwide health burden. Conventional risk factors such as smoking, hypertension, dyslipidemia and type 2 diabetes melllitus have a profound impact on the development and progression of PAD. Besides these risk factors, serum polyunsaturated fatty acids (PUFA) profile, measured as eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA), has been drawing increasing attention as a novel risk factor for atherosclerosis. EPA has unique and diverse anti-inflammatory, antiplatelet, and anti-oxidant effects, with a variety of cardiovascular and endothelial protective actions. Serum PUFA profile may serve as a simple and valuable risk prediction tool to screen the asymptomatic patients for atherosclerotic disease, including PAD. This chapter emphasizes the importance of serum PUFA profile in our Japanese patient population with femoropopliteal or infrapopliteal PAD requiring percutaneous endovascular therapy. Despite the evidence about the impact of EPA/AA ratio on PAD, the therapeutic effects of intensive purified EPA supplementation on prevention and regression of PAD are conflicting and warrant future large-scale prospective studies and randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=85019898911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019898911&partnerID=8YFLogxK

M3 - Chapter

SN - 9781634848800

SP - 85

EP - 100

BT - Peripheral Artery Disease (PAD)

PB - Nova Science Publishers, Inc.

ER -